229 related articles for article (PubMed ID: 23520486)
1. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Bradshaw-Pierce EL; Pitts TM; Kulikowski G; Selby H; Merz AL; Gustafson DL; Serkova NJ; Eckhardt SG; Weekes CD
PLoS One; 2013; 8(3):e58089. PubMed ID: 23520486
[TBL] [Abstract][Full Text] [Related]
2. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination.
Mordant P; Loriot Y; Leteur C; Calderaro J; Bourhis J; Wislez M; Soria JC; Deutsch E
Mol Cancer Ther; 2010 Feb; 9(2):358-68. PubMed ID: 20124452
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
4. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
E J; Xing J; Gong H; He J; Zhang W
Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Ng K; Tabernero J; Hwang J; Bajetta E; Sharma S; Del Prete SA; Arrowsmith ER; Ryan DP; Sedova M; Jin J; Malek K; Fuchs CS
Clin Cancer Res; 2013 Jul; 19(14):3987-95. PubMed ID: 23743569
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
Brandi G; Tavolari S; De Rosa F; Di Girolamo S; Agostini V; Barbera MA; Frega G; Biasco G
PLoS One; 2012; 7(7):e41347. PubMed ID: 22911782
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
11. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Gulhati P; Zaytseva YY; Valentino JD; Stevens PD; Kim JT; Sasazuki T; Shirasawa S; Lee EY; Weiss HL; Dong J; Gao T; Evers BM
Carcinogenesis; 2012 Sep; 33(9):1782-90. PubMed ID: 22696593
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Di Nicolantonio F; Arena S; Tabernero J; Grosso S; Molinari F; Macarulla T; Russo M; Cancelliere C; Zecchin D; Mazzucchelli L; Sasazuki T; Shirasawa S; Geuna M; Frattini M; Baselga J; Gallicchio M; Biffo S; Bardelli A
J Clin Invest; 2010 Aug; 120(8):2858-66. PubMed ID: 20664172
[TBL] [Abstract][Full Text] [Related]
14. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
15. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
16. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.
Mohseni M; Park BH
J Clin Invest; 2010 Aug; 120(8):2655-8. PubMed ID: 20664174
[TBL] [Abstract][Full Text] [Related]
18. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
[TBL] [Abstract][Full Text] [Related]
19. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
